跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

D2763

Sigma-Aldrich

双氢麦角胺 甲磺酸盐

powder

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C33H37N5O5 · CH4O3S
CAS号:
6190-39-2
分子量:
679.78
EC 号:
228-235-6
MDL编号:
MFCD00058615
UNSPSC代码:
12352200
PubChem化学物质编号:
24277913
NACRES:
NA.77

表单

powder

颜色

white

溶解性

methanol: 21 mg/mL
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 5.45 mg/mL
H2O: insoluble

SMILES字符串

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34

InChI

1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1

InChI key

ADYPXRFPBQGGAH-WVVAGBSPSA-N

基因信息

human ... DRD2(1813)

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

血管羟色胺受体激动剂；α-肾上腺素和多巴胺 D2 受体部分激动剂；血管收缩剂。
Vascular serotonin receptor agonist; vasoconstrictor.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H312 + H332

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
097K1459
105F0105

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

D Kellerman et al.
Cephalalgia : an international journal of headache, 32(2), 150-158 (2011-12-17)
Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions. However, no reported studies of such interactions with DHE administered by any route are available. The pharmacokinetics (PK)
Shashidhar Kori et al.
Clinical therapeutics, 34(9), 1920-1928 (2012-08-25)
MAP0004 is an orally inhaled investigational drug containing dihydroergotamine (DHE). Although DHE has been used for 60 years with no reported cardiac arrhythmias, a thorough QT study had not previously been performed with DHE. The objective of this study was
Bruno A Marichal-Cancino et al.
European journal of pharmacology, 692(1-3), 69-77 (2012-07-31)
It has been suggested that during a migraine attack trigeminal nerves release calcitonin gene-related peptide (CGRP), producing central nociception and vasodilatation of cranial arteries, including the extracranial branches of the external carotid artery. Since trigeminal inhibition may prevent this vasodilatation
Anick Bérard et al.
Headache, 52(7), 1085-1093 (2012-05-23)
Dihydroergotamine (DHE) is perceived to be associated with a higher risk of adverse pregnancy events, but it has significantly less vasoconstrictive and uterotonic effects compared with ergotamine, and has demonstrated no teratogenic effect in animals. The objectives of this study
Stewart J Tepper et al.
Mayo Clinic proceedings, 86(10), 948-955 (2011-10-04)
To evaluate the efficacy of MAP0004, an orally inhaled dihydroergotamine, for acute treatment of migraine when administered at various time points from within 1 hour to more than 8 hours after migraine onset. This post hoc subanalysis was conducted using
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门